GlassScriptPhysician profile
Adam J Sky
NPI 1346388667
$1,111,002.77
in general payments reported to CMS, 2019-2025
34 companies · $131K in 2025
The $131K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225K · 2020: $71K · 2021: $153K · 2022: $116K · 2023: $197K · 2024: $219K · 2025: $131K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $439K · Travel and Lodging: $66K · Consulting Fee: $26K · Food and Beverage: $16K · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $438,818.18 |
| Travel and Lodging | $65,703.10 |
| Consulting Fee | $25,972.00 |
| Food and Beverage | $16,205.59 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $508,503.40 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Avanir Pharmaceuticals, INC. | $344,354.03 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $210,801.86 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33,967.72 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $2,695.79 | 2019-2022 | |
| Biogen, INC. | $1,704.34 | 2020-2022 | |
| Abbvie INC. | $1,140.71 | 2021-2025 | Vraylar |
| Alkermes, INC. | $985.66 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $947.22 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $920.31 | 2019-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $894.74 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $738.39 | 2019-2025 | Invega Sustenna, Spravato, Invega |
| Allergan, INC. | $714.82 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $476.84 | 2019-2025 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $426.77 | 2019-2025 | Trintellix |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $224.05 | 2022-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $210.56 | 2024-2025 | Cobenfy |
| Livanova USA, INC. | $204.95 | 2022-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Noven Therapeutics, LLC | $144.49 | 2021-2024 | Xelstrym, Secuado |
| Eisai INC. | $129.17 | 2020-2021 | |
| Tris Pharma INC | $108.75 | 2022-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $97.88 | 2019-2022 | |
| Lilly USA, LLC | $96.62 | 2025 | Kisunla |
| Neos Therapeutics, LP | $79.72 | 2023-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $78.55 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $62.58 | 2023 | Qelbree |
| Idorsia Pharmaceuticals US INC | $57.34 | 2023 | Quviviq |
| Corium, LLC | $56.37 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $53.71 | 2022-2023 | Belsomra |
| Neuronetics, INC. | $35.47 | 2019 | |
| Indivior INC. | $27.98 | 2022 | |
| Shire North American Group INC | $27.40 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.26 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Sky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.